Marketresearch.biz, in its upcoming report titled, “Global Dengue Vaccines Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”, offers in-depth insights, revenue details, and other vital information regarding the dengue vaccines market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report also offers insightful and detailed information regarding the various key players operating in the global dengue vaccines market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global dengue vaccines market has been segmented on the basis of technology, distribution channel, and region. The global dengue vaccines market is projected to expand at a CAGR of X.X% from 2018 to 2027, and is expected to reach US$XXX million by the end of 2027.
According to WHO 2017, there are 390 million dengue infections per year,96 million cases are clinical infections, 2 million server dengue (also known as Dengue Haemorrhagic Fever) and 20,000 deaths and affecting people across 128 countries globally. Dengue also know by other names, such as "breakbone fever" or "dandy fever. Dengue is a mosquito born disease caused by ‘Aedes Aegypti’ species of female mosquito which live in urban habitat, breads in manmade containers. Dengue a viral infection transmitted from mosquito to human and symptoms are high fever, headache, vomiting, muscle and joint pains which are observed after three to fourteen days after getting infected. Severe dengue cause death due to plasma leaking, fluid accumulation, respiratory distress, severe bleeding, or organ impairment. Dengue viruses (DENVs) are members of the genus Flavivirus within the family Flaviviridae. There are four serotypes of viruses namely DENV-1, DENV-2, DENV-3 and DENV-4 and all are present generally in tropical and subtropical region around the world.
The demand for global dengue vaccines market is expected to increase over the coming years, owing to the increasing incidence of dengue fever, growing number of government initiatives, unplanned and uncontrolled urbanization, lack of basic amenities in communities, and poor environmental management. Also, factors such as population growth, globalization and tourism, and climate change facilitates increasing transmission of dengue anticipating in boosting demand of dengue vaccines. Factors hindering the demand of dengue vaccines are inadequate cold chain systems for storage of vaccine, standardized diagnostics practice, lack of proper surveillance system and regulatory hurdles in vaccines preparations.
Several governments are willing to incorporate dengue vaccine in public immunization programs given assured quality, safety and affordability of the vaccine. Global and National level awareness programs regarding spread and control of dengue fever. According to World Health Organization (WHO) report ‘global strategy for dengue prevention and control 2012-2020’ states that dengue mortality is expected to reduce by at least 50 percent by 2020. Introduction of dengue vaccine and expanding presence in Asia Pacific region are the current trend witnessed in dengue vaccines markets.
The global dengue vaccines market report has been segmented on the basis of technology, distribution channel and region. Currently in Asia pacific countries like Brazil, Mexico, Thailand, Singapore and India due to rapid urbanization, limited access to basic services, and climate change are the market leader for dengue vaccines. Hospitals are most common and highly revenue generating channel of distribution.
Segmentation on the basis of technology:
- Live attenuated vaccine
- Chimeric Live attenuated vaccine
- Subunit vaccine
- Inactivated vaccine
- Nucleic acid based vaccine
Segmentation on the basis of distribution channel:
- Government Institutes
Segmentation on the basis of region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2028 Revenue in US$
- Sanofi Pasteur Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Panacea Biotec Limited
- Instituto Butantan
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Limited
- GeneOne Life Science Inc.
- Medigen Vaccine Biologics Corporation
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!